In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia
Mario De Decker(University Medical Center Groningen), Filip De Vos(University Medical Center Utrecht), Rudi Dierckx(University Medical Center Groningen), Klaus Bacher, Guido Slegers(Ghent University), Hubert Thierens(Ghent University)
Cited by 29
Related Papers
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
|Molecular Neurobiology|2018|750
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
|Journal of Nuclear Medicine|2009|562
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter
|Neuro-Oncology|2022|508
Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy
|Journal of Psychopharmacology|2017|279
The Use of<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mrow><mml:mn mathvariant="bold">18</mml:mn></mml:mrow></mml:mrow></mml:math>F-FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases
|Clinical and Developmental Immunology|2013|245